GRAIL, Inc. (GRAL) vs QIAGEN N.V. (QGEN)
GRAIL, Inc. and QIAGEN N.V. are both Diagnostics & Research companies. QIAGEN N.V. is the larger, with a market value of $9.3B against $5.5B — 1.7× the size. GRAIL, Inc. has negative trailing earnings, so its P/E is not meaningful; QIAGEN N.V. trades at 22.6×. GRAIL, Inc. grew revenue faster over the last twelve months: 23.1% against 2.96%. QIAGEN N.V. has the higher net margin (19.5% vs −237.0%) and the higher return on invested capital (6.62% vs −20.8%). Across the 17 metrics below, QIAGEN N.V. leads on 13 and GRAIL, Inc. on 4.
Valuation
Profitability
| Metric | GRAL | QGEN | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | (31.31%) | 62.20% | 50.89% |
| Operating margin | (338.40%) | 21.21% | (8.57%) |
| Net margin | (236.95%) | 19.49% | (6.37%) |
| Free cash flow margin | (179.21%) | 20.98% | 0.00% |
| Return on equity | (16.12%) | 11.93% | (2.92%) |
| Return on assets | (14.12%) | 6.99% | (6.71%) |
| Return on invested capital | (20.79%) | 6.62% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack